Florida is currently home to 3847 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
Recruiting
The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower face which some individuals deem as aesthetically undesirable and can be treated by selectively weakening the masseter muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective injection of onabotulinumtoxinA (BOTOX) is in adult participants with Masseter Muscle Prominence (MMP). BOTOX is being inv... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Susan H. Weinkle MD /ID# 252063, Bradenton, Florida
Conditions: Masseter Muscle Prominence
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Panax Clinical Research, Miami Lakes, Florida
Conditions: Hypertriglyceridemia
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Panax Clinical Research, Miami Lakes, Florida
Conditions: Severe Hypertriglyceridemia
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Recruiting
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone [TSH]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/13/2024
Locations: South Florida Wellness & Clinic /ID# 256513, Margate, Florida
Conditions: Hypothyroidism
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
Recruiting
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Advanced Research, Boynton Beach, Florida
Conditions: Thyroid Eye Disease
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
Recruiting
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Advanced Clinical Research, Coral Springs, Florida
Conditions: Thyroid Eye Disease
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
Recruiting
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/13/2024
Locations: Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale Beach, Florida
Conditions: Alzheimer's Disease
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
Recruiting
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Gender:
All
Ages:
Between 60 years and 100 years
Trial Updated:
05/13/2024
Locations: Universal Axom Clinical Research, Doral, Florida
Conditions: Muscle Loss, Obesity
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
Recruiting
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their standard therapy throughout the study. Participants are put into 4 groups by chance. 3 of the 4 groups take different doses of BI 1569912. 1 group takes placebo. Placebo tablets looks like BI 1569912 but... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2024
Locations: Galiz Research, Hialeah, Florida
Conditions: Depressive Disorder, Major
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Recruiting
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Lexicon Investigational Site (119), Brandon, Florida
Conditions: Diabetic Peripheral Neuropathic Pain
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Florida Cancer Specialists - Lake Nona, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Recruiting
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).
Gender:
All
Ages:
50 years and above
Trial Updated:
05/13/2024
Locations: Florida Medical Clinic PA, Zephyrhills, Florida
Conditions: Giant Cell Arteritis, Polymyalgia Rheumatica